Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy of alpha-blocker monotherapy
and alpha-blocker + 5-alpha reductase inhibitor combination therapy in benign prostate
hyperplasia patients, and suggest guidelines of the combination therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Astellas Pharma Korea, Inc. Medical Research Collaborating Center, Seoul, Korea